Franck Rahaghi
Executive Director of Cardiopulmonary, Global Medical Affairs United Therapeutics Corp.
Seminars
Thursday 21st August 2025
Panel Discussion: Rethinking Combination Strategies in IPF: From Preclinical Models to Patient Selection
3:00 pm
With momentum building around combination approaches in IPF, this panel will explore how to design smarter strategies grounded in mechanistic complementarity, translatable models, and biomarker-driven patient selection.
Key Talking Points:
- Identifying orthogonal vs. redundant mechanisms to guide rational combination design
- Reassessing preclinical models to better evaluate multi-drug interactions, safety, and efficacy
- Using biomarkers and radiomics to refine patient stratification and predict response
- Defining when standard-of-care therapy isn’t enough and how to optimize add-on strategies for maximum impact
Thursday 21st August 2025
How Can the Evolution of Trials & Guidelines in Pulmonary Hypertension Inform Future Efforts in IPF/ILD?
12:00 pm
- Lessons from the evolution of endpoints in PH trials: from 6-minute walk test to composite and patient-centric outcomes
- Applicability of combination and sequential therapy strategies in IPF/ILD clinical development
- How changes in PH guidelines have influenced trial design – and what that could mean for future IPF/ILD guidance
